Compare ACHV & ITIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACHV | ITIC |
|---|---|---|
| Founded | N/A | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.0M | 517.8M |
| IPO Year | 2018 | 1995 |
| Metric | ACHV | ITIC |
|---|---|---|
| Price | $6.10 | $282.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $14.67 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 46.1K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 4.43% |
| EPS Growth | N/A | ★ 13.02 |
| EPS | N/A | ★ 3.20 |
| Revenue | N/A | ★ $272,755,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $86.32 |
| Revenue Growth | N/A | ★ 5.60 |
| 52 Week Low | $2.38 | $207.73 |
| 52 Week High | $7.11 | $291.44 |
| Indicator | ACHV | ITIC |
|---|---|---|
| Relative Strength Index (RSI) | 51.78 | 60.83 |
| Support Level | $4.09 | $246.61 |
| Resistance Level | $7.11 | $286.53 |
| Average True Range (ATR) | 0.40 | 7.07 |
| MACD | -0.05 | -0.88 |
| Stochastic Oscillator | 38.86 | 69.36 |
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
Investors Title Co operates in the title insurance and exchange services sectors. The Company has two reportable segments. The Company's primary business activity, and one of its reportable operating segments, is the issuance of residential and commercial title insurance through ITIC and NITIC. The company's second reportable operating segment is providing tax-deferred real property exchange services through its subsidiaries, Investors Title Exchange Corporation (ITEC) and Investors Title Accommodation Corporation (ITAC).